Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.9B
72M shares
52-week range
$15.79 – $31.34
66% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
51.2
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
www.zymeworks.comNo one on the platform currently holds ZYME.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 220,877 | $5.8M |
No one on the platform has traded ZYME yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 38.9% | 22.2% | ||||
| Profit Margin % | -76.6% | -231.5% | -250.9% | |||
| Free Cash Flow Margin % | -32.6% | -216.2% | -214.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is -6.9% on the P/E track.
At today's price, your expected annual return is +5.7% on the P/E track.
At today's price, your expected annual return is +17.1% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $313M | +155.1% | $1.46 | $0.93–$2.63 | 17.9× | 6 |
| 2027 | $334M | +6.5% | $1.31 | $-2.86–$4.73 | 19.8× | 6 |
| 2028 | $239M | -28.5% | $0.20 | $-0.60–$1.31 | 130.7× | 6 |
| 2029 | $367M | +53.9% | $1.28 | $0.85–$1.78 | 20.3× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.57 | $-0.62 | -7.9% |
| 2026-05-07 | $-0.10 | $-0.59 | -490.0% |
| 2026-03-02 | $-0.35 | $-0.55 | -57.1% |
| 2025-11-06 | $-0.30 | $-0.26 | +13.3% |
| 2025-08-07 | $-0.52 | $0.03 | +105.8% |
| 2025-05-08 | $-0.45 | $-0.30 | +33.3% |
| 2025-03-05 | $0.01 | $-0.31 | -3200.0% |
| 2024-10-31 | $-0.40 |
| $-0.39 |
| +2.5% |
| $1.3B |
| — |
| NTLAIntellia Therapeutics, Inc. | $11.36 | -4.30% | $1.6B | — |
| PHVSPharvaris N.V. | $38.06 | -2.06% | $2.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ZYME tired of winning yet? Third red day in a row. Jeez. @maplelakeduckslayer
View on StockTwits ↗
$ZYME TBPH shareholder vote for acquisition by ZYME Sept 18
View on StockTwits ↗
Zymeworks ($ZYME): the doublet clears overall survival too, one week after the FDA approval that earned 250 million dollars Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/zymeworks-stock-hub/
View on StockTwits ↗@maplelakeduckslayer @Mikelonggggggggg $ZYME desperate and deeper, No Support in sight. Beautiful rejection.
View on StockTwits ↗@maplelakeduckslayer @Mikelonggggggggg Look at $CNTB and you know whats is coming next to $ZYME
View on StockTwits ↗$ZYME where are all the cheerios at today?!? 🤪 This turd cannot even hold the 30‘s… 🤡
View on StockTwits ↗
$ZYME i wish this would stop crashing
View on StockTwits ↗
@Mikelonggggggggg I too will zip my piehole then :) $ZYME
View on StockTwits ↗$ZYME why so quiet here. :) bulls should be excited
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.